NCT00182689View on ClinicalTrials.gov

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Extensive Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
Interventions
DRUG

sorafenib tosylate

Given orally

Trial Locations (1)

97239

SWOG, Portland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00182689 - Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter